$23.81
1.245.49%
Last update: Oct 9, 4:00 PM
$22.84
0.271.2%

Tango Therapeutics (TNGX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.32 | $-0.32 | $-0.32 | $-0.04 |
| Actual | $-0.37 | $-0.32 | $-0.29 | $0.14 |
| Surprise | -15.6% | 0.00% | +9.38% | +450.0% |
| Revenue | ||||
| Estimate | $1.6M | $578090 | $500400 | $42.2M |
| Actual | $0 | $0 | $0 | $53.8M |
| Surprise | -100.0% | -100.0% | -100.0% | +27.5% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.35 | $-0.37 | $-0.38 | $-0.40 |
| Revenue | ||||
| Consensus | — | — | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.37 | $-0.32 | -15.6 % |
| Q1 | May 13, 2026 | $-0.32 | $-0.32 | 0.00 % |
| Q4 | Mar 5, 2026 | $-0.29 | $-0.32 | 9.38 % |
| Q3 | Nov 4, 2025 | $0.14 | $-0.04 | 450.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $0 | $1.56M | -100.0 % |
| Q1 | May 13, 2026 | $0 | $578.09K | -100.0 % |
| Q4 | Mar 5, 2026 | $0 | $500.40K | -100.0 % |
| Q3 | Nov 4, 2025 | $53.81M | $42.22M | 27.5 % |